Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that CEO Todd C. Brady will participate in key investor conferences in September 2022. The events include Citi's 17th Annual BioPharma Conference on September 7 in Boston, and H.C. Wainwright's 24th Annual Global Investment Conference on September 14 in New York. Dr. Brady's presentation at the latter is set for 10:00 a.m. ET and can be accessed via Aldeyra's website. Aldeyra focuses on innovative treatments for immune-mediated diseases, with products like reproxalap and ADX-629 in various clinical stages.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences in September:

• Citi’s 17th Annual BioPharma Conference (1x1 meetings only)
  Wednesday, September 7, 2022
  Boston, Mass.

• H.C. Wainwright 24th Annual Global Investment Conference
  Wednesday, September 14, 2022
  New York, NY

Dr. Brady’s presentation at the H.C. Wainwright 24th Annual Global Investment Conference is scheduled to begin at 10:00 a.m. ET Wednesday, September 14, 2022. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. A replay will be available following the presentation and will be archived on the website for 90 days.

About Aldeyra

Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906006042/en/

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: (857) 383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What investor conferences will Aldeyra Therapeutics participate in September 2022?

Aldeyra Therapeutics will attend Citi's 17th Annual BioPharma Conference on September 7 and H.C. Wainwright's 24th Annual Global Investment Conference on September 14.

When will Dr. Todd C. Brady present at the H.C. Wainwright conference?

Dr. Todd C. Brady's presentation at the H.C. Wainwright Global Investment Conference is scheduled for September 14, 2022, at 10:00 a.m. ET.

How can I watch Aldeyra's presentation at the investor conference?

To view Aldeyra's presentation live, visit the Investors & Media section of the Aldeyra website. A replay will be available for 90 days.

What is Aldeyra Therapeutics known for?

Aldeyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for immune-mediated diseases, including products like reproxalap and ADX-629.

What are the lead product candidates of Aldeyra Therapeutics?

The lead product candidates of Aldeyra Therapeutics include reproxalap, targeting dry eye disease and allergic conjunctivitis, and ADX-629, aimed at systemic immune-mediated diseases.